BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

BCRX 10.15 +0.37 (3.78%)
price chart
Reaction to Confirmed Ebola Case in U.S. � UPDATED
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) was up 5% at $9.78 in the after-hours, but that was after a 6.7% drop to $9.78 in regular trading.
First Ebola Case In US; Tekmira, NewLink, and BioCryst Surge After-Hours  Bidness ETC
Buzz Stocks: Tekmira Pharmaceuticals Corporation, BioCryst Pharmaceuticals ...  Schaeffers Research (blog)
Related articles »  
Heavy Early Morning Activity On Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Related articles »  
How Will CDC Control Ebola? Tekmira's Drug May Be the Answer
Sarepta Therapeutics Inc (SRPT) is also gaining pre-market and is already up 8.7%, while BioCryst Pharmaceuticals Inc.'s (BCRX) has gained 16.5%.
Ahead of the Bell: Ebola treatment makers rise  Businessweek
After gov't discloses first US-diagnosed case of Ebola, shares of cos ...  Minneapolis Star Tribune
Related articles »  
Biocryst Pharmaceuticals Inc. (BCRX) Is Rising After U.S. Ebola Case Confirmed
The Centers for Disease Control confirmed the first case of Ebola in the U.S. late Tuesday afternoon. Biocryst Pharmaceuticals Inc. (BCRX: Quote), which is working to develop an Ebola treatment, is now up 1.62 on 78K shares. Biocryst Pharmaceuticals ...
Falling NASDAQ Stocks: BioCryst Pharmaceuticals,...
GDP Insider covers every aspect of news and information, from breaking national and international crises through to in-depth features, sports, business, entertainment and technology articles, weather reports, travel services, movie reviews, rural news ...
Related articles »  
Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Related articles »  
Morning Buzz: Tekmira Pharmaceuticals (TKMR), Biocryst Pharmaceuticals ...
In premarket-hours however, the stock is up 9% changing hands at $10.60. BioCryst Pharmaceuticals has a PEG and t-12 price-to-sales ratio of (1.76) and 39.25, respectively.
BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares fell sharply after the World Health Organization posted a draft document suggesting it would not advise the company's Ebola therapy for use in humans until further safety data is available.
Related articles »  
Ebola Theme: BioCryst Pharmaceuticals (BCRX), NewLink Genetics (NLNK ...
Albany, New York (10/01/2014) - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the several drug companies working frantically to develop a solution for Ebola Virus Disease (EVD).
Stocks Alert: BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), Sarepta ...
Lakeway, NY - (MARKET NEWS CALL) - 10/01/2014� Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S.
Related articles »